| Autor: |
Andoh S; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Yokoyama K; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Uchida S; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Makiyama J; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Kawamata T; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Yasui H; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Ota Y; Department of Pathology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Imai Y; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo., Tojo A; Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo. |
| Abstrakt: |
Although classic Hodgkin's lymphoma (CHL) sometimes develops after treatment for multiple myeloma (MM), simultaneous diagnosis of both malignancies is extremely rare without previous treatment history. Here we describe a case of a 54-year-old female who complained of left cervical lymphadenopathy. Biopsy specimen from the left cervical lymph node revealed mixed-cellularity CHL. Bone marrow aspirate comprised 10.3% plasma cells. She was diagnosed with MM due to involved: uninvolved serum free light chain ratio of >100. She achieved complete response for CHL after 4 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy along with 30 Gy of involved-field radiotherapy. Three years later, bortezomib, lenalidomide, and dexamethasone (VRd-lite) therapy was initiated for MM. Severe neutropenia during her 1st cycle prompted a dosage reduction of lenalidomide and bortezomib. Partial response was achieved after 4 cycles of VRd-lite followed by high-dose melphalan/autologous stem cell transplantation. No severe adverse events were recorded. This was followed by 4 cycles of carfilzomib, lenalidomide, and dexamethasone therapy, which resulted in complete remission. As the number of elderly people increases, multiple myeloma patients with previous history of other malignancies would increase. Our case has shown that VRd-lite therapy may be suitable for those patients. |
